The risk of T2D was somewhat greater for high-intensity statins (rosuvastatin, atorvastatin, simvastatin) compared to low- and medium-intensity statins. Importantly, an increased risk of incident T2D by statins was comparable with the risk of T2D of other drugs (beta-blockers and thiazide diuretics) used for the prevention of CVD.
Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three
Can J Anesth. 2024. DOI: 10.1007/s Trulicity, T2D SQ Injection x1 weekly, Delayed Ozempic, Wegovy, others, T2D/Obesity
T2D-related complications. 3. Adherence and persistence defined. 3 Extent of sub-optimal T2D drug therapy adherence and persistence. 4 Economic burden of sub
Type 2 diabetes (T2D) is a complex chronic disease characterized by considerable phenotypic heterogeneity. year of T2D diagnosis and drug use as covariates in the model. To assess the time to
The increased patient cost burden at age 65 years and a modest reduction in overall T2D drug utilization suggest that as people with T2D age into Medicare, there is potentially an increase in nonadherence and diabetes complications, the authors write. Abstract/Full Text
The GLP-1 drugs include semaglutide, sold as Ozempic for type 2 diabetes (T2D) and as Wegovy for weight loss, and liraglutide, sold as Saxenda for weight loss and as Victoza for T2D.
(T2D). In this guidance, antidiabetic drugs refer to drugs intended to improve glycemic control, including drugs intended to reduce diabetes
The GLP-1 drugs include semaglutide, sold as Ozempic for type 2 diabetes (T2D) and as Wegovy for weight loss, and liraglutide, sold as Saxenda for weight loss and as Victoza for T2D.
Comments